Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234

Am J Ophthalmol. 2022 Oct:242:254. doi: 10.1016/j.ajo.2022.07.018. Epub 2022 Aug 14.
No abstract available

Publication types

  • Published Erratum